Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 46.96 USD -2.02% Market Closed
Market Cap: 6B USD
Have any thoughts about
Halozyme Therapeutics Inc?
Write Note

Wall Street
Price Targets

HALO Price Targets Summary
Halozyme Therapeutics Inc

Wall Street analysts forecast HALO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HALO is 63.69 USD with a low forecast of 50.5 USD and a high forecast of 78.75 USD.

Lowest
Price Target
50.5 USD
8% Upside
Average
Price Target
63.69 USD
36% Upside
Highest
Price Target
78.75 USD
68% Upside

HALO Last Price Targets
Halozyme Therapeutics Inc

The latest public price target was made on Nov 15, 2024 by Joseph Catanzaro from Piper Sandler , who expects HALO stock to rise by 11% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Joseph Catanzaro
Piper Sandler
52 USD
Upside 11%
1 month ago
Nov 15, 2024
Piper Sandler Reiterates Neutral Rating on Halozyme Therapeutics (HALO)
StreetInsider
Mohit Bansal
Wells Fargo
58 USD
Upside 24%
6 months ago
Jun 7, 2024
Halozyme Therapeutics (HALO) PT Raised to $58 at Wells Fargo
StreetInsider
Joseph Catanzaro
Piper Sandler
51 USD
Upside 9%
6 months ago
Jun 7, 2024
Halozyme downgraded to Neutral after rally at Piper Sandler
TheFly
Mitchell Kapoor
H.C. Wainwright
65 USD
Upside 38%
6 months ago
Jun 7, 2024
Halozyme Therapeutics (HALO) PT Raised to $65 at H.C. Wainwright
StreetInsider
Corinne Jenkins
Goldman Sachs
44 USD
Downside 6%
6 months ago
Jun 6, 2024
Halozyme price target raised to $44 from $41 at Goldman Sachs
TheFly
Joseph Catanzaro
Piper Sandler
Price Target 52 USD
Upside/Downside 11%
View Source
Mohit Bansal
Wells Fargo
Price Target 58 USD
Upside/Downside 24%
View Source
Joseph Catanzaro
Piper Sandler
Price Target 51 USD
Upside/Downside 9%
View Source
Mitchell Kapoor
H.C. Wainwright
Price Target 65 USD
Upside/Downside 38%
View Source
Corinne Jenkins
Goldman Sachs
Price Target 44 USD
Upside/Downside 6%
View Source
Halozyme Therapeutics Inc Competitors:
Price Targets
AMGN
Amgen Inc
28% Upside
OCX
OncoCyte Corp
92% Upside
SVE
Synthaverse SA
56% Upside
1952
Everest Medicines Ltd
31% Downside
CPRX
Catalyst Pharmaceuticals Inc
55% Upside
SWTX
SpringWorks Therapeutics Inc
92% Upside
2256
Abbisko Cayman Ltd
165% Upside
BIOCON
Biocon Ltd
4% Upside

Revenue
Forecast

Revenue Estimate
Halozyme Therapeutics Inc

For the last 8 years the compound annual growth rate for Halozyme Therapeutics Inc's revenue is 25%. The projected CAGR for the next 4 years is 19%.

25%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Halozyme Therapeutics Inc

The compound annual growth rate of Halozyme Therapeutics Inc's operating income for the next 4 years is 33%.

N/A
Past Growth
33%
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Halozyme Therapeutics Inc

The compound annual growth rate of Halozyme Therapeutics Inc's net income for the next 4 years is 38%.

N/A
Past Growth
38%
Estimated Growth
Estimates Accuracy
7%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HALO's stock price target?
Price Target
63.69 USD

According to Wall Street analysts, the average 1-year price target for HALO is 63.69 USD with a low forecast of 50.5 USD and a high forecast of 78.75 USD.

What is Halozyme Therapeutics Inc's Revenue forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Halozyme Therapeutics Inc's revenue is 25%. The projected CAGR for the next 4 years is 19%.

What is Halozyme Therapeutics Inc's Operating Income forecast?
Projected CAGR
33%

The compound annual growth rate of Halozyme Therapeutics Inc's operating income for the next 4 years is 33%.

What is Halozyme Therapeutics Inc's Net Income forecast?
Projected CAGR
38%

The compound annual growth rate of Halozyme Therapeutics Inc's net income for the next 4 years is 38%.

Back to Top